Unknown

Dataset Information

0

Tumor Targeting with an isoDGR-Drug Conjugate.


ABSTRACT: Herein we report the first example of an isoDGR-drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin ?V ?3 . Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val-Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin ?V ?3 receptor (IC50 =11.0?nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti-proliferative assays on two isogenic cancer cell lines characterized by different integrin ?V ?3 expression: human glioblastoma U87 (?V ?3 +) and U87 ?3 -KO (?V ?3 -). The isoDGR-PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD-PTX conjugate 4 (TI=2.4).

SUBMITTER: Zanella S 

PROVIDER: S-EPMC5488297 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Herein we report the first example of an isoDGR-drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin α<sub>V</sub> β<sub>3</sub> . Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val-Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin α<sub>V</sub> β<sub>3</sub> receptor (IC<sub>50</sub> =11.0 nm). The tumor targeting ability of conjugat  ...[more]

Similar Datasets

| S-EPMC5827777 | biostudies-literature
| S-EPMC6411448 | biostudies-literature
| S-EPMC6277321 | biostudies-literature
| S-EPMC5127683 | biostudies-literature
| S-EPMC6025988 | biostudies-literature
| S-EPMC9537177 | biostudies-literature
| S-EPMC5934552 | biostudies-literature
| S-EPMC8487729 | biostudies-literature
| S-EPMC7854894 | biostudies-literature